We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Serum Test for Ovarian Cancer Helps Determine Type of Required Surgery

By LabMedica International staff writers
Posted on 17 Sep 2009
Ovarian cancer can be detected in a pelvic mass that is already known to require surgery, helping patients and health care professionals decide what type of surgery should be done and by whom.

Called OVA1, the qualitative serum test for ovarian cancer combines the results of five immunoassays into a single numerical score. More...
The test is indicated for women who meet the following criteria: the patient is over age 18, an ovarian adnexal mass is present for which surgery is planned, and the patient has not yet been referred to an oncologist.

The immunoassay identifies five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II). An algorithm is then used to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.

OVA1test was developed by Vermillion, Inc. (Freemont, CA, USA) a molecular diagnostics company, in cooperation with Quest Diagnostics (Madison, NJ, USA), a provider of cancer diagnostics. Quest Diagnostics has exclusive rights to offer the test to the clinical reference laboratory market in the U.S. for three years. The U.S. Food and Drug Administration (FDA) has cleared the OVA1 test, as an indication of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even when radiological test results fail to indicate malignancy.

The test should not be used without an independent clinical/radiological evaluation. It is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

Vermillion, Inc. is dedicated to the discovery, development, and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat, and improve outcomes for patients. Vermillion has diagnostic programs in oncology, hematology, cardiology, and women's health.

Quest Diagnostics is a provider of diagnostic testing, information, and services that patients and doctors need to make better healthcare decisions. The company offers access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its medical and scientific staff.

Related Links:
Vermillion, Inc.
Quest Diagnostics


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Pipette
Accumax Smart Series
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LiDia-SEQ aims to deliver near-patient NGS testing capabilities to hospitals, labs and clinics (Photo courtesy of DNAe)

World's First NGS-Based Diagnostic Platform Fully Automates Sample-To-Result Process Within Single Device

Rapid point-of-need diagnostics are of critical need, especially in the areas of infectious disease and cancer testing and monitoring. Now, a direct-from-specimen platform that performs genomic analysis... Read more

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Pathology

view channel
Image: The AI tool advances precision diagnostics by linking genetic mutations directly to disease types (Photo courtesy of Shutterstock)

AI Tool Simultaneously Identifies Genetic Mutations and Disease Type

Interpreting genetic test results remains a major challenge in modern medicine, particularly for rare and complex diseases. While existing tools can indicate whether a genetic mutation is harmful, they... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.